COVID-19 VACCINE DEVELOPMENT THROUGH IMMUNOINFORMATICS GUIDED MULTIPLE EPITOPING AND DEMONSTRATION OF DRUG REPURPOSING THROUGH MOLECULAR DOCKING

Abstract

Coronavirus-2 (SARS-CoV-2) is responsible for the symptoms of COVID-19. Almost every nation has been infected by SARS-CoV-2. The COVID-19 pandemic has prompted researchers to concentrate on the development of a vaccine and treatment techniques by becoming intimately familiar with the infection's biology. In order to minimize COVID-19 mortality and provide global immunity, a highly efficacious SARS-CoV-2 vaccine is imperative. The lengthy and costly process of developing vaccines could be sped up with immunoinformatics techniques. There have been advances in immunoinformatics tools used for reverse vaccinology to develop a SARS-CoV-2 vaccine, including Vaxijen, IEDB, NetCTL 1.2, PEP-FOLD, and studies of the development of MHC-I and II binding epitopes, among others. A drug repurposing strategy would reduce time and cost compared to drug discovery from scratch. It is an effective strategy for leveraging existing medications. Immunoinformatics may help identify T cell and B cell epitopes with more confidence, leading to fewer experiments and higher dependability for identifying vaccine candidates.